Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ocubless
- Development stage
- Unknown
- Lead developer
- Centaur Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ocubless is an oral antioxidant and mineral supplement marketed by Centaur Pharmaceuticals. It is formulated to support eye health and reduce the risk of progression in individuals with moderate to advanced age-related macular degeneration (AMD). The standard formulation contains a combination of essential vitamins, minerals, and carotenoids, including vitamin C (ascorbic acid), vitamin E (tocopherol), zinc, copper, lutein, and zeaxanthin. These ingredients work synergistically to protect retinal and macular tissues from oxidative stress and filter harmful high-energy blue light. Ocubless is available in oral dosage forms, such as tablets and capsules.
- Brand names
- OcublessOcubless Plus
Beyond the preview
Go deeper on Ocubless.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ocubless.